XML 17 R7.htm IDEA: XBRL DOCUMENT v3.23.3
Condensed Consolidated Statements of Cash Flows - USD ($)
 3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2023
Mar. 31, 2023
Sep. 30, 2022
Mar. 31, 2022
Sep. 30, 2023
Sep. 30, 2022
Dec. 31, 2022
Cash flows from operating activities:              
Net loss $ (33,929,864) $ (40,649,317) $ (37,783,896) $ (79,073,719) $ (110,113,714) $ (225,354,926)  
Adjustments to reconcile net loss to net cash used in operating activities:              
Depreciation         2,051,962 2,776,672  
Amortization of intangible assets         145,417 376,911  
Amortization of operating lease right-of-use assets         1,130,932 993,949  
Impairment of goodwill 10,513,371   0   10,513,371 0  
Impairment of intangible assets         1,984,444 0  
Non-cash stock-based compensation         8,806,188 19,281,108  
Non-cash interest on senior convertible notes         (126,511) (126,511)  
Amortization of discounts on investments         (3,641,765) (584,816)  
Loss on sales of short-term investments         3,853,691 1,265,669  
Loss on disposal of fixed assets         364,422 157,666  
Gain on remeasurement of investment in Geneos         0 (165,215)  
(Gain) loss on equity investment in affiliated entity (214,374)   305,061   (987,758) 1,776,804  
Share of net loss in Geneos 0   0   0 2,165,213  
Net unrealized (gain) loss on available-for-sale equity securities 219,337   1,833,284   (3,921,819) 10,641,026  
Changes in operating assets and liabilities:              
Accounts receivable, including from affiliated entities         9,594,021 (2,048,642)  
Prepaid expenses and other current assets, including from affiliated entities         39,285,174 (19,146,007)  
Other assets         78,729 723,808  
Accounts payable and accrued expenses, including due to affiliated entities         (50,641,862) 27,323,827  
Accrued clinical trial expenses         (5,582,888) 3,159,580  
Deferred revenue, including from affiliated entity         0 (85,989)  
Operating lease right-of-use assets and liabilities, net         (2,147,175) (1,930,270)  
Grant funding liability, including from affiliated entity         1,265,375 (1,770,768)  
Other liabilities         0 695,522  
Net cash used in operating activities         (98,089,766) (179,875,389)  
Cash flows from investing activities:              
Purchases of investments         (174,250,213) (203,549,807)  
Proceeds from sale or maturity of investments         235,912,707 261,938,897  
Purchases of capital assets         (320,898) (804,044)  
Proceeds from sale of capital assets         6,071,000 0  
Investment in Geneos         0 (1,999,998)  
Net cash provided by investing activities         67,412,596 55,585,048  
Cash flows from financing activities:              
Proceeds from issuance of common stock, net of issuance costs         3,623,462 76,287,314  
Proceeds from stock option exercises         0 283,022  
Taxes paid related to net share settlement of equity awards         (466,646) (1,397,631)  
Net cash provided by financing activities         3,156,816 75,172,705  
Effect of exchange rate changes on cash and cash equivalents         (4,403) (37,903)  
Decrease in cash and cash equivalents         (27,524,757) (49,155,539)  
Cash and cash equivalents, beginning of period   $ 46,329,359   $ 71,143,778 46,329,359 71,143,778 $ 71,143,778
Cash and cash equivalents, end of period $ 18,804,602   $ 21,988,239   18,804,602 21,988,239 $ 46,329,359
Supplemental disclosures:              
Amounts accrued for purchases of fixed assets         0 262,191  
Interest paid         1,066,975 1,066,975  
Issuance of common stock as part of litigation settlement         $ 14,000,000 $ 0